Download WGU D124 FNP OSCE SOAP Note & Practice Exam 2026/2027 Verified Answers & Explanations (GRA and more Exams Nursing in PDF only on Docsity!
WGU D124 FNP OSCE SOAP Note & Practice Exam 2026/
Verified Answers & Explanations (GRADED A+)
This comprehensive study package provides a detailed blueprint of the WGU D124 Midterm OSCE SOAP note focusing on Diabetes Mellitus and Dyslipidemia management. It includes meticulously formatted multiple- choice questions complete with verified, updated answers and in-depth rationales tailored for high-scoring clinical reasoning. Designed for maximum utility, this resource serves as the ultimate preparation tool for mastering family nurse practitioner diagnostic documentation and clinical guidelines. Question 1 A 54-year-old male with type 2 diabetes mellitus presents for a routine follow-up. His latest lipid panel reveals an LDL cholesterol level of 130 mg/dL. He has no history of clinical atherosclerotic cardiovascular disease (ASCVD), and his 10-year ASCVD risk is calculated at 8.5%. According to the American Diabetes Association (ADA) guidelines, what is the most appropriate initial management for his dyslipidemia? A) Lifestyle modifications alone for 3 months B) Initiate low-intensity statin therapy C) Initiate moderate-intensity statin therapy D) Initiate high-intensity statin therapy
ANSWER: C) Initiate moderate-intensity statin therapy
EXPLANATION: For patients aged 40–75 years with diabetes mellitus
and without established clinical ASCVD, the ADA guidelines
recommend initiating at least a moderate-intensity statin regardless
of the baseline LDL level to reduce cardiovascular risk. Option A is
incorrect because lifestyle modifications alone are insufficient for
diabetic patients in this age bracket. Option B is incorrect because
low-intensity statins are generally not recommended as standard
first-line preventative therapy in diabetes. Option D is incorrect
because high-intensity statins are typically reserved for diabetic
patients with multiple ASCVD risk factors or a 10-year risk score ≥
Question 2 During a comprehensive diabetic foot exam on a 62 - year-old female patient, the nurse practitioner utilizes a 10-g monofilament. Loss of protective sensation (LOPS) is noted at 4 out of 10 tested sites. Which of the following is the most appropriate diagnostic conclusion and subsequent clinical management plan? A) Peripheral arterial disease; refer to vascular surgery immediately B) Diabetic peripheral neuropathy; implement daily self-foot inspections and prescribe a rigid therapeutic shoe insert C) Diabetic peripheral neuropathy; educate on daily foot inspection, check footwear, and schedule a podiatry referral
C) SGLT2 inhibitors (e.g., Empagliflozin) D) Thiazolidinediones (e.g., Pioglitazone)
ANSWER: C) SGLT2 inhibitors (e.g., Empagliflozin)
EXPLANATION: Sodium-glucose cotransporter 2 (SGLT2) inhibitors
have demonstrated robust clinical evidence in slowing the
progression of diabetic kidney disease (DKD), reducing
macroalbuminuria, and lowering the risk of a significant eGFR
decline. They are strongly recommended for patients with type 2
diabetes and chronic kidney disease with albuminuria. Options A, B,
and D do not offer verified, direct secondary renal protective
benefits or independent reduction of UACR progression.
Question 4 A 39-year-old male patient presents to the clinic with yellowish, plaque- like cutaneous lesions located over his Achilles tendons and extensor surfaces of his elbows. His fasting lipid panel reveals a total cholesterol of 340 mg/g and an LDL-C of 250 mg/dL. These physical presentation markers are most pathognomonic for which underlying medical condition? A) Acute pancreatitis B) Familial hypercholesterolemia C) Diabetic dermopathy D) Severe hypertriglyceridemia
ANSWER: B) Familial hypercholesterolemia
EXPLANATION: The clinical description details tendon xanthomas,
which are collections of cholesterol deposits commonly found on the
Achilles tendon and extensor surfaces. Paired with an LDL
cholesterol level > 190 mg/dL, this presentation highly points to
familial hypercholesterolemia (a genetic dyslipidemia). Option A is
incorrect because pancreatitis is associated with eruptive
xanthomas driven by high triglycerides, not tendon xanthomas.
Option C describes hyperpigmented macules on shins. Option D
presents with eruptive papular xanthomas rather than tendinous
plaques.
Question 5 When reviewing the laboratory results of a patient diagnosed with uncontrolled type 2 diabetes mellitus and severe dyslipidemia, the nurse practitioner notes a fasting triglyceride level of 850 mg/dL. What is the immediate primary clinical risk that must be addressed in the treatment plan before optimizing LDL reduction? A) Acute myocardial infarction B) Ischemic stroke C) Acute pancreatitis D) Diabetic ketoacidosis
ANSWER: C) Acute pancreatitis
EXPLANATION: When serum triglyceride levels exceed 500 mg/dL
secondary prevention in very high-risk patients (those with
established ASCVD and diabetes), the target LDL-C is < 55 mg/dL (or
at minimum < 70 mg/dL depending on specific stratification). If the
goal is not met on a maximally tolerated high-intensity statin, non-
statin therapies like Ezetimibe must be added. Option A uses
obsolete target goals. Option C is premature because Ezetimibe
should be added before escalating to an injectable PCSK9 inhibitor.
Option D is clinically counterindicated as the patient tolerates the
high-intensity therapeutic dosing well.
Question 7 During an initial evaluation, a patient presents with multiple hyperpigmented, velvety plaques localized around the posterior neck and axillary folds. What physiological state does this skin finding primarily signify to the clinician during the physical exam? A) Severe hypertriglyceridemia B) Absolute insulin deficiency C) Peripheral insulin resistance D) Systemic allergic reaction
ANSWER: C) Peripheral insulin resistance
EXPLANATION: The physical exam finding described is acanthosis
nigricans. It is caused by hyperinsulinemia, where high circulating
levels of insulin interact with insulin-like growth factor receptors on
keratinocytes and fibroblasts, causing cutaneous proliferation. It
serves as a visual marker for peripheral insulin resistance and
metabolic syndrome. Option A is associated with eruptive
xanthomas. Option B represents type 1 diabetes presentation
(wasting, cachexia). Option D presents with urticaria or pruritus.
Question 8 A 50-year-old male diabetic patient is initiated on Rosuvastatin 20 mg daily for dyslipidemia management. Four weeks into therapy, he returns complaining of diffuse, symmetrical muscle aches and weakness in his proximal upper and lower extremities. He denies dark urine or trauma. What is the most appropriate next step in his clinical assessment? A) Order a serum creatine kinase (CK) level and temporarily hold the statin B) Reassure the patient that muscle soreness is normal and will pass C) Increase the statin dose to overcome localized muscle resistance D) Switch the patient to Simvastatin 40 mg immediately
ANSWER: A) Order a serum creatine kinase (CK) level and
temporarily hold the statin
EXPLANATION: The patient presents with clinical signs of statin-
associated muscle symptoms (SAMS), which range from benign
myalgia to dangerous rhabdomyolysis. Assessing a baseline creatine
kinase (CK) level is critical to rule out muscle breakdown, and
holding the drug preserves safety while determining etiology. Option
B is unsafe because ignoring severe myopathy can lead to acute
pathology present. Option D features distinct signs like papilledema
and macular stars.
Question 10 A 55-year-old female patient with a history of type 2 diabetes mellitus presents for management of her hypertension. Her clinic blood pressure readings over two separate visits average 144/88 mmHg. She has trace microalbuminuria. Which of the following agents is selected as first-line therapy to manage her hypertension while addressing renal protection? A) Amlodipine B) Lisinopril C) Metoprolol D) Hydrochlorothiazide
ANSWER: B) Lisinopril
EXPLANATION: For patients with diabetes mellitus, hypertension, and
microalbuminuria, an Angiotensin-Converting Enzyme (ACE) inhibitor
(like Lisinopril) or an Angiotensin II Receptor Blocker (ARB) is the
mandated first-line therapy. These agents dilate the efferent
arteriole in the kidney, decreasing intraglomerular pressure and
reducing protein excretion. Options A, C, and D are effective
antihypertensives but do not provide the same preferential
mechanism for slowing diabetic nephropathy progression.
Question 11 Which of the following lab combinations is the most appropriate and cost- effective annual screening bundle for evaluating microvascular renal injury and long-term glycemic control in an established, asymptomatic type 2 diabetic patient? A) Serum bun, creatinine, and fasting plasma glucose B) Estimated GFR, random urine albumin-to-creatinine ratio (UACR), and HbA1c C) 24-hour urine protein clearance and oral glucose tolerance test D) Renal ultrasound and serum insulin levels
ANSWER: B) Estimated GFR, random urine albumin-to-creatinine
ratio (UACR), and HbA1c
EXPLANATION: ADA guidelines recommend an annual assessment of
renal function via estimated GFR (derived from serum creatinine)
and microvascular endothelial integrity via a spot urine UACR,
coupled with regular HbA1c checks to evaluate continuous 3-month
glycemic stability. Option A lacks a specific quantification for
microalbuminuria. Option C is cumbersome and unnecessary for
routine screening. Option D does not track early-stage functional
microvascular diabetic damage.
Question 12
C) BMI of 24.9, LDL 190 mg/dL, HDL 60 mg/dL D) Total cholesterol 260 mg/dL, HbA1c 5.5%, Potassium 4.2 mEq/L
ANSWER: B) Waist circumference 42 inches (male), BP 138/
mmHg, Fasting Glucose 112 mg/dL
EXPLANATION: Metabolic syndrome requires at least 3 of 5 criteria:
abdominal obesity (waist circumference >40 inches in men, >
inches in women), elevated triglycerides (≥ 150 mg/dL), reduced
HDL (<40 mg/dL in men, <50 mg/dL in women), elevated blood
pressure (≥ 130/85 mmHg), and elevated fasting glucose (≥ 100
mg/dL). Option B contains 3 correct parameters. Options A, C, and D
do not meet the multivariable threshold criteria.
Question 14 When counseling a patient newly diagnosed with type 2 diabetes mellitus regarding lifestyle modifications, what is the minimum duration and intensity of physical activity recommended weekly by the American Diabetes Association (ADA) to improve insulin sensitivity? A) 60 minutes of high-intensity interval training split into 2 days B) 150 minutes of moderate-intensity aerobic physical activity spread over at least 3 days per week C) 300 minutes of low-intensity walking with no more than 1 day of rest D) 75 minutes of vigorous resistance training once a week
ANSWER: B) 150 minutes of moderate-intensity aerobic physical
activity spread over at least 3 days per week
EXPLANATION: The ADA standard recommendation for adults is at
least 150 minutes/week of moderate-intensity aerobic physical
activity (such as brisk walking), distributed over at least 3
days/week, with no more than 2 consecutive days without activity.
Options A, C, and D do not reflect the standard evidence-based
targets for optimizing cardiorespiratory fitness and insulin actions.
Question 15 A 60-year-old male with type 2 diabetes and dyslipidemia returns for evaluation. His HbA1c has increased to 8.2% despite taking Metformin 1000 mg twice daily. He notes a strong personal desire to avoid weight gain and has a history of mild heart failure. Which of the following agents would be most appropriate to add next? A) Pioglitazone B) Glipizide C) Empagliflozin D) Saxagliptin
ANSWER: C) Empagliflozin
EXPLANATION: Empagliflozin is an SGLT2 inhibitor that promotes
weight loss via glucosuria and is clinically proven to reduce heart
failure hospitalizations and cardiovascular mortality. Option A
(Pioglitazone) is contraindicated in heart failure due to fluid
A 52-year-old male patient on maximum dose Metformin and Atorvastatin requires treatment for high triglycerides (380 mg/dL) that remain elevated despite lifestyle modifications. The clinician decides to prescribe Fenofibrate. Which physiological monitoring profile must be followed closely due to co-administration risks? A) Complete Blood Count for leukopenia B) Liver Function Tests and Creatine Kinase due to risk of hepatotoxicity and myopathy C) Serum potassium for hypokalemia D) Thyroid Stimulating Hormone for hypothyroidism
ANSWER: B) Liver Function Tests and Creatine Kinase due to risk of
hepatotoxicity and myopathy
EXPLANATION: Concomitant use of statins and fibrates increases the
clinical risk of muscle injury (myopathy, rhabdomyolysis) and
hepatic transaminase elevations. Baseline and periodic liver function
and muscle enzyme checking are necessary. Fenofibrate is
preferred over Gemfibrozil because it interferes less with statin
glucuronidation. Options A, C, and D are not primary physiological
systems compromised by this drug interaction.
Question 18 A diabetic patient complains of persistent early-morning hyperglycemia. The provider instructs the patient to check their blood glucose at 3:00 AM for several days. The 3:00 AM readings average 54 mg/dL. This clinical
presentation represents which phenomenon, and what is the correct therapeutic adjustment? A) Dawn Phenomenon; increase the evening long-acting insulin dose B) Somogyi Effect; decrease the evening long-acting insulin dose or provide a bedtime snack C) Insulin resistance; switch from human insulin to insulin analogues D) Diabetic Gastroparesis; add a prokinetic agent before bedtime
ANSWER: B) Somogyi Effect; decrease the evening long-acting
insulin dose or provide a bedtime snack
EXPLANATION: The Somogyi effect occurs when nocturnal
hypoglycemia (indicated by the low 3:00 AM reading) triggers a
counter-regulatory hormonal surge (epinephrine, glucagon,
cortisol), causing rebound hyperglycemia by morning. Treatment
requires reducing the evening insulin or adding a snack. The Dawn
Phenomenon (Option A) features normal or elevated 3:00 AM
glucose levels driven by physiological growth hormone release.
Options C and D do not address this nocturnal glycemic pattern.
Question 19 Which of the following clinical signs discovered during a peripheral vascular assessment of a diabetic patient's lower extremities is highly suggestive of advanced lower extremity arterial insufficiency? A) Bilateral 2+ pitting edema and hyperpigmented stasis dermatitis B) Warm, erythematous calf with a positive Homans' sign
contraindicated in pregnancy due to potential teratogenicity, as
cholesterol synthesis is crucial for fetal development. A patient
planning pregnancy must stop statin therapy before conception.
Metformin (Option A) and Insulin (Option B) are safe options used to
maintain tight glycemic targets during gestation. Option D is an
analgesic without specialized reproductive contraindications.
Question 21 A 55-year-old male with type 2 diabetes mellitus and a history of a myocardial infarction 2 years ago presents for a follow-up. His fasting lipid panel shows an LDL cholesterol level of 78 mg/dL while taking Atorvastatin 40 mg daily. According to secondary prevention guidelines, what is the most appropriate next step in his pharmacological management? A) Maintain the current Atorvastatin 40 mg dose as LDL is under 100 mg/dL B) Discontinue Atorvastatin and initiate Ezetimibe 10 mg daily C) Increase Atorvastatin to 80 mg daily or add Ezetimibe to target an LDL < 55 mg/dL D) Change Atorvastatin to Pravastatin 40 mg daily to reduce side effect risk
ANSWER: C) Increase Atorvastatin to 80 mg daily or add Ezetimibe
to target an LDL < 55 mg/dL
EXPLANATION: For patients with established clinical ASCVD
(secondary prevention), high-intensity statin therapy (such as
Atorvastatin 80 mg) is required, and the recommended LDL target is
< 55 mg/dL. Since his LDL is 78 mg/dL, his therapy needs to be
intensified. Option A uses outdated targets. Option B removes the
foundational statin. Option D de-escalates to a moderate-intensity
statin, which is inappropriate for secondary prevention in a very
high-risk patient.
Question 22 A 61-year-old female with type 2 diabetes presents with a blood pressure of 146/92 mmHg. A repeat reading 15 minutes later confirms 144/ mmHg. Urinalysis reveals microalbuminuria (UACR 45 mg/g). She is not currently taking any antihypertensive medications. Which medication class should be selected first? A) Thiazide diuretic (e.g., Chlorthalidone) B) Angiotensin-Converting Enzyme (ACE) inhibitor (e.g., Lisinopril) C) Beta-blocker (e.g., Metoprolol) D) Calcium channel blocker (e.g., Amlodipine)
ANSWER: B) Angiotensin-Converting Enzyme (ACE) inhibitor (e.g.,
Lisinopril)
EXPLANATION: ACE inhibitors or ARBs are the first-line
antihypertensive choices for patients with diabetes and
microalbuminuria. They provide specific renal protective benefits by
dilating the efferent arteriole, which lowers intraglomerular
